{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:46:24Z","timestamp":1762508784448,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ctro.2022.05.001","type":"journal-article","created":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T11:58:28Z","timestamp":1653134308000},"page":"104-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["High-dose-rate brachytherapy boost for elderly patients with intermediate to high-risk prostate cancer: 5-year clinical outcome of the PROSTAGE cohort"],"prefix":"10.1016","volume":"35","author":[{"given":"Delphine","family":"Marotte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jocelyn","family":"Gal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renaud","family":"Schiappa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu","family":"Gautier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rabia","family":"Boulahssass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Eve","family":"Chand-Fouche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Michel","family":"Hannoun-Levi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2022.05.001_b0005","unstructured":"Cancer today [Internet]. [cited 2021 Jun 18]. Available from: http:\/\/gco.iarc.fr\/today\/home."},{"key":"10.1016\/j.ctro.2022.05.001_b0010","unstructured":"Cancer Tomorrow [Internet]. [cited 2021 Jun 18]. Available from: https:\/\/gco.iarc.fr\/tomorrow\/en\/dataviz\/isotype?cancers=27&single_unit=50000&age_start=14."},{"key":"10.1016\/j.ctro.2022.05.001_b0015","unstructured":"Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology in: Journal of the National Comprehensive Cancer Network Volume 17 Issue 5 (2019) [Internet]. [cited 2021 Jun 27]. Available from: https:\/\/jnccn.org\/view\/journals\/jnccn\/17\/5\/article-p479.xml."},{"issue":"6","key":"10.1016\/j.ctro.2022.05.001_b0020","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1200\/JCO.2005.06.154","article-title":"Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate","volume":"23","author":"Sathya","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2022.05.001_b0025","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2012.01.007","article-title":"Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer","volume":"103","author":"Hoskin","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2022.05.001_b0030","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.radonc.2020.09.047","article-title":"Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results","volume":"154","author":"Hoskin","year":"2021","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2022.05.001_b0035","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiation Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ctro.2022.05.001_b0040","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ijrobp.2013.11.004","article-title":"Receipt of guideline-concordant treatment in elderly prostate cancer patients","volume":"88","author":"Chen","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ctro.2022.05.001_b0045","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0090-4295(03)00690-3","article-title":"Continued undertreatment of older men with localized prostate cancer","volume":"62","author":"Schwartz","year":"2003","journal-title":"Urology"},{"issue":"17","key":"10.1016\/j.ctro.2022.05.001_b0050","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1200\/JCO.2003.09.034","article-title":"Do Older Men Benefit From Curative Therapy of Localized Prostate Cancer?","volume":"21","author":"Alibhai","year":"2003","journal-title":"JCO"},{"issue":"2","key":"10.1016\/j.ctro.2022.05.001_b0055","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2010.30.2075","article-title":"Impact of Age at Diagnosis on Prostate Cancer Treatment and Survival","volume":"29","author":"Bechis","year":"2011","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.ctro.2022.05.001_b0060","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/cncr.11884","article-title":"Is there age bias in the treatment of localized prostate carcinoma?","volume":"100","author":"Alibhai","year":"2004","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/j.ctro.2022.05.001_b0065","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1002\/cncr.30948","article-title":"Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer","volume":"123","author":"Yang","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ctro.2022.05.001_b0070","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eururo.2014.12.026","article-title":"Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer","volume":"68","author":"Bratt","year":"2015","journal-title":"Eur Urol"},{"issue":"18","key":"10.1016\/j.ctro.2022.05.001_b0075","doi-asserted-by":"crossref","first-page":"6646","DOI":"10.1002\/cam4.3297","article-title":"Increased curative treatment is associated with decreased prostate cancer-specific and overall mortality in senior adults with high-risk prostate cancer; results from a national registry-based cohort study","volume":"9","author":"Aas","year":"2020","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.ctro.2022.05.001_b0080","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.juro.2010.09.014","article-title":"Prostate Cancer in Men 70 Years Old or Older, Indolent or Aggressive: Clinicopathological Analysis and Outcomes","volume":"185","author":"Brassell","year":"2011","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.ctro.2022.05.001_b0085","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.critrevonc.2003.05.006","article-title":"External beam radiotherapy in elderly patients with clinically localized prostate adenocarcinoma: age is not a problem","volume":"48","author":"Villa","year":"2003","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"1","key":"10.1016\/j.ctro.2022.05.001_b0090","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.radonc.2005.06.001","article-title":"3D conformal radiation therapy for prostate cancer in elderly patients","volume":"76","author":"Geinitz","year":"2005","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2022.05.001_b0095","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.critrevonc.2009.04.004","article-title":"Curative external beam radiotherapy in patients over 80 years of age with localized prostate cancer: A retrospective rare cancer network study","volume":"74","author":"Nguyen","year":"2010","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"6","key":"10.1016\/j.ctro.2022.05.001_b0100","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/jrr\/rrv040","article-title":"Clinical outcomes of helical tomotherapy for super-elderly patients with localized and locally advanced prostate cancer: comparison with patients under 80 years of age","volume":"56","author":"Okonogi","year":"2015","journal-title":"J Radiat Res"},{"key":"10.1016\/j.ctro.2022.05.001_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctro.2022.04.006","article-title":"Irradiation of localized prostate cancer in the elderly: A systematic literature review","volume":"35","author":"Marotte","year":"2022","journal-title":"Clinical and Translational Radiation Oncology"},{"issue":"11","key":"10.1016\/j.ctro.2022.05.001_b0110","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1002\/cncr.24974","article-title":"Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer","volume":"116","author":"Hoffman","year":"2010","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ctro.2022.05.001_b0115","doi-asserted-by":"crossref","first-page":"S337","DOI":"10.1016\/j.ijrobp.2009.07.773","article-title":"Improved Outcome with Combined Pelvic External Beam Radiation and HDR Boost Brachytherapy or IMART Compared with Conventional External Beam Prostate Radiation for Elderly Men with High-intermediate to High-risk Prostate Cancer","volume":"75","author":"Stromberg","year":"2009","journal-title":"Int J Radiation Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.ctro.2022.05.001_b0120","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.brachy.2019.01.013","article-title":"Improved survival for patients with prostate cancer receiving high-dose-rate brachytherapy boost to EBRT compared with EBRT alone","volume":"18","author":"Kent","year":"2019","journal-title":"Brachytherapy"},{"issue":"6","key":"10.1016\/j.ctro.2022.05.001_b0125","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/apm.12533","article-title":"International Society of Urological Pathology (ISUP) grading of prostate cancer - An ISUP consensus on contemporary grading","volume":"124","author":"Egevad","year":"2016","journal-title":"APMIS"},{"issue":"1-2","key":"10.1016\/j.ctro.2022.05.001_b0130","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.canrad.2021.11.017","article-title":"External radiotherapy for prostatic cancers","volume":"26","author":"de Crevoisier","year":"2022","journal-title":"Cancer Radiother"},{"issue":"5","key":"10.1016\/j.ctro.2022.05.001_b0135","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.brachy.2017.06.013","article-title":"High-dose-rate brachytherapy boost for prostate cancer: Comparison of three different fractionation schemes","volume":"16","author":"Falk","year":"2017","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ctro.2022.05.001_b0140","doi-asserted-by":"crossref","first-page":"203","DOI":"10.5114\/jcb.2013.38657","article-title":"Prostate cancer boost using high-dose-rate brachytherapy: early toxicity analysis of 3 different fractionation schemes","volume":"4","author":"Hijazi","year":"2013","journal-title":"jcb"},{"issue":"2","key":"10.1016\/j.ctro.2022.05.001_b0145","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.radonc.2018.04.031","article-title":"Combined high dose rate brachytherapy and external beam radiotherapy for clinically localised prostate cancer","volume":"128","author":"Strouthos","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2022.05.001_b0150","doi-asserted-by":"crossref","DOI":"10.3390\/jcm7110424","article-title":"Radiothrerapy for Elderly Patients Aged \u226575 Years with Clinically Localized Prostate Cancer-Is There a Role of Brachytherapy?","author":"Yamazaki","year":"2018","journal-title":"J Clin Med"},{"key":"10.1016\/j.ctro.2022.05.001_b0155","first-page":"67","article-title":"Radiotherapy for elder patients aged \u226580 with clinically localized prostate cancer - Brachytherapy enhanced late GU toxicity especially in elderly","volume":"25","author":"Yamazaki","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"issue":"12","key":"10.1016\/j.ctro.2022.05.001_b0160","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s00345-015-1553-0","article-title":"Patterns of use and patient characteristics: brachytherapy for localized prostate cancer in octo- and nonagenarians","volume":"33","author":"Valdivieso","year":"2015","journal-title":"World J Urol"},{"issue":"3","key":"10.1016\/j.ctro.2022.05.001_b0165","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0360-3016(01)02390-2","article-title":"Acute and late toxicity in men \u226570 years old compared with men < 70 years old treated with high dose rate prostate brachytherapy boost and pelvic external irradiation for prostate cancer","volume":"51","author":"Stromberg","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ctro.2022.05.001_b0170","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s00066-018-1380-5","volume":"195","author":"L\u00f6ser","year":"2019","journal-title":"Strahlenther Onkol"},{"issue":"33","key":"10.1016\/j.ctro.2022.05.001_b0175","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.1200\/JCO.2006.07.9954","article-title":"Patient and Treatment Factors Associated With Complications After Prostate Brachytherapy","volume":"24","author":"Chen","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2022.05.001_b0180","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ijrobp.2008.01.017","article-title":"Prostate brachytherapy in men > or =75 years of age","volume":"72","author":"Merrick","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.ctro.2022.05.001_b0185","first-page":"194","article-title":"Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology","volume":"60","author":"Levine","year":"2010","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.ctro.2022.05.001_b0190","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ijrobp.2009.04.085","article-title":"Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy","volume":"77","author":"Nanda","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ctro.2022.05.001_b0195","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ctro.2022.05.001_b0200","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ijrobp.2009.01.045","article-title":"D\u2019Amico AV. Survival Following Radiation and Androgen Suppression Therapy for Prostate Cancer in Healthy Older Men: Implications for Screening Recommendations","volume":"76","author":"Nguyen","year":"2010","journal-title":"Int J Radiation Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ctro.2022.05.001_b0205","doi-asserted-by":"crossref","first-page":"239.e9","DOI":"10.1016\/j.urolonc.2018.01.004","article-title":"External beam radiotherapy with or without androgen deprivation therapy in elderly patients with high metastatic risk prostate cancer","volume":"36","author":"Dell\u2019Oglio","year":"2018","journal-title":"Urologic Oncology: Seminars and Original Investigations"},{"issue":"3","key":"10.1016\/j.ctro.2022.05.001_b0210","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3390\/cancers12030635","article-title":"Can Comprehensive Geriatric Assessment Predict Tolerance of Radiotherapy for Localized Prostate Cancer in Men Aged 75 Years or Older?","volume":"12","author":"Goineau","year":"2020","journal-title":"Cancers (Basel)"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630822000386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630822000386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:09:47Z","timestamp":1762502987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630822000386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":42,"alternative-id":["S2405630822000386"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2022.05.001","relation":{},"ISSN":["2405-6308"],"issn-type":[{"type":"print","value":"2405-6308"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-dose-rate brachytherapy boost for elderly patients with intermediate to high-risk prostate cancer: 5-year clinical outcome of the PROSTAGE cohort","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2022.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}]}}